To establish whether preventive treatment given at EPI prevented either severe anaemia or malaria.
Ethics approval received on the 15th December 1999.
Sulphadoxine-pyrimethamine or placebo given at EPI visits DPT2, DPT3 and measles. Collection of sera to establish impact (if any) upon EPI antigens.